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grams), and male gender. Increasing length of mechanical ventilation and birth 
weight 500-999 grams were associated with ever receiving inhaled 
corticosteroids. CONCLUSIONS: Bronchodilator and ICS use are common for 
infants with BPD at U.S. Children's hospitals, although frequency of use varies 
significantly. The effectiveness and safety of their use in these infants needs to 
be determined, in order to develop evidence-based recommendations.  
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OBJECTIVES: Research has shown that employees caring for older adults may 
experience physiological and psychosocial effects and require family supports 
that may vary across different ethnic groups. The purpose of this study was to 
explore differences in caregiving skills; caregiver burden; self-efficacy; and 
quality of life, health and well-being of African-American and Caucasian 
caregivers who are providing care for an older adult. METHODS: A total of 153 
Caucasian and African-American adults currently working and caring for an 
older adult were personally interviewed. RESULTS: The typical working caregiver 
was a 49-year-old woman caring for her 79-year-old mother with African-
American caregivers more likely to be living in the same household. In the past 
six months, African-American caregivers were more likely to have taken off 
work more than twenty hours and used the telephone at work one to five times a 
week for caregiving responsibilities. Caregiver Self Efficacy was positively related 
to Caregiver Rewards (r=.424, p<0.001) and negatively related to Burden (r=-0.310, 
p<0.001) for both groups. Regarding Caregiving Skills, African-American 
caregivers rated their skills in communicating with their older loved one more 
highly than Caucasian (beta=.332, p<0.001) and were more likely to have taken 
more than 20 hours off work (beta =0.201, p<0.05). African-American caregivers 
were less confident of finding information and good resources for their elder 
care recipient and themselves than Caucasian caregivers (beta = -0.175, p<0.05 
and beta = -0.183, p<0.05 respectively). Those caregivers with greater self-efficacy 
and greater caregiver rewards reported greater quality of life. There were 
significant differences in caregiver burden with African-Americans feeling a 
greater level of burden. CONCLUSIONS: The differing effects of elder caregiving 
among African-Americans and Caucasian caregivers may require different, more 
personalized caregiver interventions and supports to reduce the caregiver 
burden, increase feelings of rewards, and improve the quality of life for both 
ethnic groups.  
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OBJECTIVES: This study estimates lipid profile changes and abnormalities in 
treatment naïve HIV patients initiating atazanavir/ritonavir (ATV/r) versus 
darunavir/ritonavir (DRV/r) using a matched indirect comparison. METHODS: 
Two similarly designed randomized trials were identified. Individual patient-
level data were available for the CASTLE trial comparing ATV/r (n=430) and 
lopinavir/r (LPV/r) (n=438); published summary data were used from the 
ARTEMIS trial comparing DRV/r (n=343) and LPV/r (n=346). To adjust for cross-
trial differences, CASTLE patients were re-weighted to match summary baseline 
characteristics in ARTEMIS. Lipid profile changes and serious (grade 2-4) lipid 
laboratory abnormalities (LA) at 48 weeks were compared between balanced trial 
populations after matching. If significant differences in LPV/r outcomes existed 
after matching, the differences between active treatments and LPV/r were 
compared across trials. RESULTS: Data from all patients in the two trials were 
included. Before matching, CASTLE patients at baseline had a higher proportion 
of HIV-1 RNA>100,000 copies/mL, a lower proportion CDC class C, and lower 
median CD4 cell count than ARTEMIS patients. An unadjusted cross-trial 
comparison at 48 weeks showed that ATV/r and DRV/r had similar changes in 
total cholesterol, low density lipoprotein (LDL), and triglycerides, but ATV/r had 
significantly lower rates of total cholesterol LA (7% vs.13%, p=0.008) and LDL LA 
(8% vs. 13%, p=0.040). After balancing mean baseline characteristics, ATV/r and 
DRV/r at 48 weeks had similar changes in total cholesterol, LDL, and triglycerides 
(adjusted difference [AD]= -7.19, -7.11 and 7.59 mg/dL, respectively) and similar 
percentages of grade 2-4 triglycerides and cholesterol LAs (AD=0% and 1%, 
respectively); however, ATV/r had a significantly lower rate of serious LDL LA 
(AD=-9%, p=0.006). CONCLUSIONS: While the overall lipid profiles of ATV/r and 
DRV/r were similar at 48 weeks in this matching-adjusted indirect comparison, 
ATV/r had a significantly lower rate of serious LDL LA.  
 
PIN2  
THE IMPACT OF CLOSTRIDIUM DIFFICILE INFECTION ON MEDICARE 
BENEFICIARY HEALTH CARE UTILIZATION AND OUTCOMES  
Drozd EM1, Hemal S2, Thomas SM2, Braithwaite SF1 
1Avalere Health, LLC, Washington, DC, USA, 2Optimer Pharmaceuticals, Inc., Jersey City, NJ, 
USA  
OBJECTIVES: Clostridium difficile infection (CDI) primarily occurs in elderly 
adults and contributes to excess patient mortality, readmissions, hospital costs, 
and post-discharge costs. Two-thirds of CDI hospitalizations are for patients 
with CDI as a secondary diagnosis (“secondary CDI”). This study assesses the 
burden of illness of secondary CDI on outcomes and healthcare utilization for 
hospitalized Medicare beneficiaries. METHODS: Using a 5% random sample of 
Medicare claims from 2009–2010, patients with and without secondary CDI and 
no prior hospitalization within the previous 30 days were identified. Prior year 
claims data were used to describe case mix and baseline characteristics. 
Propensity scores were developed to match CDI and non-CDI patients on 
potential confounding factors. Outcomes of interest were: index episode length-
of-stay (LOS), emergency department (ED) and ICU use, inpatient mortality, post-
discharge mortality, readmissions, and acute care use. RESULTS: The final 
sample size after a propensity score match was 3262 patients in each patient 
cohort. Secondary CDI was associated with an 80% increase in hospital LOS, and 
a greater than 160% increase in ICU days, relative to patients without CDI. 
Secondary CDI was associated with an 80% increase in both inpatient and 30-day 
post-discharge mortality. Inpatient mortality for immunocompromized patients 
was 130% greater than like patients without CDI. Secondary CDI was associated 
with a 41% increase in 30-day CDI readmission rates and a 46% increase in the 
number of readmissions per admission. Immunocompromised patients with 
secondary CDI were associated with a 180% increase in post-discharge CDI-
related ED visits and a 65% increase in post-discharge skilled nursing facility 
admissions. CONCLUSIONS: Secondary CDI in hospitalized Medicare 
beneficiaries is associated with considerable negative impacts on LOS, mortality, 
readmission rates, and post-discharge utilization compared to matched controls. 
Consequently, comprehensive CDI prevention and treatment strategies are 
needed to decrease resource utilization and burden in patients who develop 
secondary CDI.  
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OBJECTIVES: Billing and claims data can potentially be used to identify surgical 
site infections (SSIs) for quality improvement initiatives. We investigated the 
effect that variation in procedure coding by providers and facilities has on the 
calculated SSI incidence. METHODS: We established a retrospective cohort study 
of individuals aged 6 months – 64 years with ICD-9-CM procedure or CPT-4® 
codes from facility and/or provider claims for umbilical, femoral/inguinal, or 
incisional/ventral herniorrhaphy from 1/1/2004-12/31/2010 using private insurer 
claims data. SSIs within 90 days were identified by ICD-9-CM diagnosis codes, 
with censoring for other surgeries within 90 days. Complex surgeries with 
additional procedures performed on or before the herniorrhaphy date during a 
hospitalization were excluded. RESULTS: 155,748 non-complex herniorrhaphy 
procedures were initially identified based on distinct procedure dates >7 days 
apart. The number of distinct procedures was reduced to 144,220 after removing 
procedures with no supportive evidence for operation (e.g., anesthesia, operating 
room revenue codes, pathology; n=4,609) and surgeries coded for >1 hernia site 
or unclassified (n=6,919). The percentage of procedures complicated by SSI was 
compared according to the stringency of identification of hernia site. Using all 
claims coded for herniorrhaphy (facility and/or provider), 1.23% (363/29,582) of 
umbilical, 0.48% (433/90,231) of femoral/inguinal, and 4.00% (976/24,407) of 
incisional/ventral procedures were complicated by SSI within 90 days. In 
contrast, the percentages of procedures complicated by SSI were 1.17% 
(297/25,323) for umbilical, 0.46% (367/79,063) for femoral/inguinal, and 4.18% 
(752/17,981) for incisional/ventral herniorrhaphy when agreement between the 
provider and facility procedure coding was required to define the hernia site. 
CONCLUSIONS: Use of claims data to determine SSI rates requires careful 
classification of procedures, particularly when characteristics of the surgical 
procedure are important risk factors for infection.  
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OBJECTIVES: Multiple sclerosis (MS) is characterized by autoimmune mediated 
demyelination of the central nervous system, and affects nearly 300,000 
individuals in the United States (US). Immunosuppressive MS therapy often 
leads to infections, which in turn may cause relapse or exacerbation of MS 
symptoms. This study is the first to evaluate the magnitude of the association 
between MS and serious infections in a US population. METHODS: Adult patients 
with MS, within the US Veterans Health Administration (VHA) system from 1999-
2010 were identified. Those without encounters 6 months or more before the 
first diagnosis were excluded. Each MS patient was matched, on age and sex, 
with up to 4 non-MS patients. Cox Proportional Hazards regression models were 
developed to assess the influence of MS on serious infections identified by ICD-9 
code. An infection was considered serious when listed as a hospital admission 
diagnosis in the VHA inpatient setting. Our regression models controlled for 
patient demographic characteristics, comorbid conditions, drug exposures, 
disability status, and health care utilization. RESULTS: Our analysis cohort 
consisted of 7,743 MS and 30,972 non-MS patients. Mean age was 53.8 (SD 13.4) 
years and 80.7% were male. Race was known in 40.8%; of which 80.2% were 
white, 16.0% black, and 3.8% variant ethnicities. The incidence of overall serious 
infections was 18.7 (95% CI=17.2-20.3) and 10.0 (95% CI=9.5-10.6) per 1,000 
person-years for MS and non-MS patients, respectively. Regression models 
revealed that MS patients were at greater risk for overall serious infections 
(HR=1.54, p<0.001) as well as serious respiratory (HR=1.31, p=0.01), urinary tract 
